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Abstract 
Introduction:  Ventilator-associated pneumonia is defined as a pneumonia occurring in 
patients within 48 hours or more after intubation with an endotracheal tube or 
tracheostomy tube and which not present before. The main objective of this study was to 
determine prevalence, predisposing factors and outcomes for ventilator associated 
pneumonia in an internal intensive care unit in a tertiary hospital. 
Material and Methods: In this retrospective review, all adult intensive care unit 
admitted patients at Ali Asghar Hospital with clinically and radiologically suspected 
ventilator-associated pneumonia between March 2009 and May 2010 were considered. 
The following data were recorded for each patient: demographic data, culture densities, 
chest radiological findings, pathogen(s), age, white blood cell count (WBC), presence of 
comorbid diseases, duration of hospital stay prior to diagnosis, and hospital survival. 
Data was assessed with SPSS software version 15 compatible for windows.             
Results: There were 49 patients in this study and most of the patients (69.3%) were 
males. Most of the patients (65.3%) were in more than 60 years age group of whom 
males were dominant. The most common risk factor was smoking, nasogastric tube, 
prolong duration of hospitalization, hospital admissions more than 2 times, prolong 
duration of intensive care unit admission, decreased level of consciousness and prolong 
ventilator support. The most common organism isolated was acinetobacter. Most of the 
patients were died (59.1%) of whom most were males. 
Discussion and conclusion: This study demonstrated that ventilator associated 
pneumonia is an important nosocomial infection among patients receiving mechanical 
ventilation in a community hospital and it is associated with greater hospital mortality 
rates and longer lengths of stay in the intensive care unit and hospital. Prevention is better 
than cure. Ventilator associated pneumonia is a well preventable disease and a proper 
approach decreases the hospital stay, cost, morbidity and mortality.                         
Key Words: Ventilator-associated pneumonia, endotracheal tube, intensive care unit, 
pathogen 
Chapter 1: 
Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.1. Ventilator-Associated Pneumonia: 
                           Most research on Ventilator-Associated Pneumonia (VAP) has focused 
on illness in the hospital setting. However, the information and principles based on this 
research can be applied to Healthcare-Associated Pneumonia (HCAP) not associated with 
ventilator use as well. The main rationale for the new designation HCAP is that the 
pathogens and treatment strategies for VAP are more similar to those for Hospital-
Acquired Pneumonia (HAP) than to those for pure CAP. The greatest difference between 
VAP and HCAP/HAPand the greatest similarity of VAP to CAPis the return to 
dependence on expectorated sputum for a microbiologic diagnosis, which is further 
complicated by the frequent colonization with pathogens among patients in the hospital 
or other health careassociated settings (1).  
1.1.1. Etiology: 
                              Potential etiologic agents of VAP include both multi drug resistance 
(MDR) and non-MDR bacterial pathogens. The non-MDR group is nearly identical to the 
pathogens found in severe CAP; it is not surprising that such pathogens predominate if 
VAP develops in the first 57 days of the hospital stay. However, if patients have other 
risk factors for HCAP, MDR pathogens are a consideration, even early in the hospital 
course. The relative frequency of individual MDR pathogens can vary significantly from 
hospital to hospital and even between different critical care units within the same 
institution. Many hospitals have problems with P. aeruginosa and MRSA, but other MDR 
pathogens are often institution-specific (1).  
 
 
 
 
Table 1-1 Microbiologic Causes of Ventilator-Associated Pneumonia 
 
 
Non-MDR Pathogens MDR Pathogens 
Streptococcus pneumoniae  Pseudomonas aeruginosa  
Other Streptococcus spp.   MRSA 
Haemophilus influenzae  Acinetobacter spp.  
MSSA  Antibiotic-resistant Enterobacteriaceae 
Antibiotic-sensitive Enterobacteriaceae Enterobacter spp.  
Escherichia coli  ESBL-positive strains 
Klebsiella pneumoniae  Klebsiella spp.  
Proteus spp.  Legionella pneumophila  
Enterobacter spp.  Burkholderia cepacia  
Serratia marcescens  Aspergillus spp.  
 
 
Note: ESBL, extended-spectrum -lactamase; MDR, multidrug-resistant; MRSA, 
methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive S. aureus. 
Less commonly, fungal and viral pathogens cause VAP, most frequently affecting 
severely immunocompromised patients. Rarely, community-associated viruses cause 
miniepidemics, usually when introduced by ill health care workers (1). 
1.1.2. Epidemiology: 
                          Pneumonia is a common complication among patients requiring 
mechanical ventilation. Prevalence estimates vary between 6 and 52 cases per 100 
patients, depending on the population studied. On any given day in the ICU, an average 
of 10% of patients will have pneumoniaVAP in the overwhelming majority of cases. 
The frequency of diagnosis is not static but changes with the duration of mechanical 
ventilation, with the highest hazard ratio in the first 5 days and a plateau in additional 
cases (1% per day) after ~2 weeks. However, the cumulative rate among patients who 
remain ventilated for as long as 30 days is as high as 70%. These rates often do not 
reflect the recurrence of VAP in the same patient. Once a ventilated patient is transferred 
to a chronic care facility or to home, the incidence of pneumonia drops significantly, 
especially in the absence of other risk factors for pneumonia (1).  
                          Three factors are critical in the pathogenesis of VAP: colonization of the 
oropharynx with pathogenic microorganisms, aspiration of these organisms from the 
oropharynx into the lower respiratory tract, and compromise of the normal host defense 
mechanisms. Most risk factors and their corresponding prevention strategies pertain to 
one of these three factors (1).  
Table 1-2 Pathogenic Mechanisms and Corresponding Prevention Strategies for 
Ventilator-Associated Pneumonia 
 
 
Pathogenic Mechanism Prevention Strategy 
Oropharyngeal colonization 
with pathogenic bacteria 
  
  Elimination of normal flora Avoidance of prolonged antibiotic courses 
  Large-volume oropharyngeal 
aspiration around time of 
intubation  
Short course of prophylactic antibiotics for comatose 
patientsa 
  
  Gastroesophageal reflux Postpyloric enteral feedingb; avoidance of high gastric 
residuals, prokinetic agents 
  
  Bacterial overgrowth of 
stomach 
Avoidance of gastrointestinal bleeding due to 
prophylactic agents that raise gastric pHb; selective 
decontamination of digestive tract with nonabsorbable 
antibioticsb 
  
Cross-infection from other 
colonized patients 
Hand washing, especially with alcohol-based hand rub; 
intensive infection control educationa; isolation; proper 
cleaning of reusable equipment 
  
Large-volume aspiration Endotracheal intubation; avoidance of sedation; 
decompression of small-bowel obstruction 
Microaspiration around 
endotracheal tube 
  
  Endotracheal intubation Noninvasive ventilationa 
  
  Prolonged duration of 
ventilation 
Daily awakening from sedation,a weaning protocolsa 
  
  Abnormal swallowing 
function 
Early percutaneous tracheostomya 
  
  Secretions pooled above 
endotracheal tube 
Head of bed elevateda; continuous aspiration of 
subglottic secretions with specialized endotracheal 
tubea; avoidance of reintubation; minimization of 
sedation and patient transport 
  
Altered lower respiratory host 
defenses 
Tight glycemic controla; lowering of hemoglobin 
transfusion threshold; specialized enteral feeding 
formula 
  
 
 
aStrategies demonstrated to be effective in at least one randomized controlled trial. 
bStrategies with negative randomized trials or conflicting results. 
                             The most obvious risk factor is the endotracheal tube (ET), which 
bypasses the normal mechanical factors preventing aspiration. While the presence of an 
ET may prevent large-volume aspiration, microaspiration is actually enhanced by 
secretions pooling above the cuff. The ET and the concomitant need for suctioning can 
damage the tracheal mucosa, thereby facilitating tracheal colonization. In addition, 
pathogenic bacteria can form a glycocalyx biofilm on the ET surface that protects them 
from both antibiotics and host defenses. The bacteria can also be dislodged during 
suctioning and can reinoculate the trachea, or tiny fragments of glycocalyx can embolize 
to distal airways, carrying bacteria with them (1). 
                               In a high percentage of critically ill patients, the normal 
oropharyngeal flora is replaced by pathogenic microorganisms. The most important risk 
factors are antibiotic selection pressure, cross-infection from other infected/colonized 
patients or contaminated equipment, and malnutrition (1). 
                                How the lower respiratory tract defenses become overwhelmed 
remains poorly understood. Almost all intubated patients experience microaspiration and 
are at least transiently colonized with pathogenic bacteria. However, only around one-
third of colonized patients develop VAP. Severely ill patients with sepsis and trauma 
appear to enter a state of immunoparalysis several days after admission to the ICUa 
time that corresponds to the greatest risk of developing VAP. The mechanism of this 
immunosuppression is not clear, although several factors have been suggested. 
Hyperglycemia affects neutrophil function, and recent trials suggest that keeping the 
blood sugar close to normal with exogenous insulin may have beneficial effects, 
including a decreased risk of infection. More frequent transfusions, especially of 
leukocyte-depleted red blood cells, also affect the immune response positively (1).  
1.1.3. Clinical Manifestations: 
                           The clinical manifestations of VAP are generally the same as for all 
other forms of pneumonia: fever, leukocytosis, increase in respiratory secretions, and 
pulmonary consolidation on physical examination, along with a new or changing 
radiographic infiltrate. The frequency of abnormal chest radiographs before the onset of 
pneumonia in intubated patients and the limitations of portable radiographic technique 
make interpretation of radiographs more difficult than in patients who are not intubated. 
Other clinical features may include tachypnea, tachycardia, worsening oxygenation, and 
increased minute ventilation (1). 
1.1.4. Diagnosis: 
1.1.4.1. Clinical Diagnosis: 
                           No single set of criteria is reliably diagnostic of pneumonia in a 
ventilated patient. The inability to identify such patients compromises efforts to prevent 
and treat VAP and even calls into question estimates of the impact of VAP on mortality 
rates (1). 
                          Application of clinical criteria consistently results in overdiagnosis of 
VAP, largely because of three common findings in at-risk patients: (1) tracheal 
colonization with pathogenic bacteria in patients with ETs, (2) multiple alternative causes 
of radiographic infiltrates in mechanically ventilated patients, and (3) the high frequency 
of other sources of fever in critically ill patients. The differential diagnosis of VAP 
includes a number of entities, such as atypical pulmonary edema, pulmonary contusion 
and/or hemorrhage, hypersensitivity pneumonitis, ARDS, and pulmonary embolism. 
Clinical findings in ventilated patients with fever and/or leukocytosis may have 
alternative causes, including antibiotic-associated diarrhea, sinusitis, urinary tract 
infection, pancreatitis, and drug fever. Conditions mimicking pneumonia are often 
documented in patients in whom VAP has been ruled out by accurate diagnostic 
techniques. Most of these alternative diagnoses do not require antibiotic treatment; 
require antibiotics different from those used to treat VAP; or require some additional 
intervention, such as surgical drainage or catheter removal, for optimal management (1).  
                             This diagnostic dilemma has led to debate and controversy. The major 
question is whether a quantitative-culture approach as a means of eliminating false-
positive clinical diagnoses is superior to the clinical approach enhanced by principles 
learned from quantitative-culture studies. The recent IDSA/ATS guidelines for HCAP 
suggest that either approach is clinically valid (1). 
1.1.4.2. Quantitative-Culture Approach: 
                             The essence of the quantitative-culture approach is to discriminate 
between colonization and true infection by determining the bacterial burden. The more 
distal in the respiratory tree the diagnostic sampling, the more specific the results and 
therefore the lower the threshold of growth necessary to diagnose pneumonia and exclude 
colonization. For example, a quantitative endotracheal aspirate yields proximate samples, 
and the diagnostic threshold is 106 cfu/mL. The protected specimen brush method, in 
contrast, obtains distal samples and has a threshold of 103 cfu/mL. Conversely, 
sensitivity declines as more distal secretions are obtained, especially when they are 
collected blindly (i.e., by a technique other than bronchoscopy). Additional tests that may 
increase the diagnostic yield include Gram's stain, differential cell counts, staining for 
intracellular organisms, and detection of local protein levels elevated in response to 
infection (1).  
                                Several studies have compared patient cohorts managed by the 
various quantitative-culture methods. While these studies documented issues of relative 
sensitivity and specificity, outcomes were not significantly different for the various 
groups of patients. The IDSA/ATS guidelines have suggested that all these methods are 
appropriate and that the choice depends on availability and local expertise (1). 
                                 The Achilles heel of the quantitative approach is the effect of 
antibiotic therapy. With sensitive microorganisms, a single antibiotic dose can reduce 
colony counts below the diagnostic threshold. Recent changes in antibiotic therapy are 
the most significant. After 3 days of consistent antibiotic therapy for another infection 
prior to suspicion of pneumonia, the accuracy of diagnostic tests for pneumonia is 
unaffected. Conversely, colony counts above the diagnostic threshold during antibiotic 
therapy suggest that the current antibiotics are ineffective. Even the normal host response 
may be sufficient to reduce quantitative-culture counts below the diagnostic threshold by 
the time of sampling. In short, expertise in quantitative-culture techniques is critical, with 
a specimen obtained as soon as pneumonia is suspected and before antibiotic therapy is 
initiated or changed (1). 
                                  In a study comparing the quantitative with the clinical approach, use 
of bronchoscopic quantitative cultures resulted in significantly less antibiotic use at 14 
days after study entry and lower rates of mortality and severity-adjusted mortality at 28 
days. In addition, more alternative sites of infection were found in patients randomized to 
the quantitative-culture strategy. A critical aspect of this study was that antibiotic 
treatment was initiated only in patients whose gram-stained respiratory sample was 
positive or who displayed signs of hemodynamic instability. Fewer than half as many 
patients were treated for pneumonia in the bronchoscopy group, and only one-third as 
many microorganisms were cultured (1). 
1.1.4.3. Clinical Approach: 
                                The lack of specificity of a clinical diagnosis of VAP has led to 
efforts to improve the diagnostic criteria. The Clinical Pulmonary Infection Score (CPIS) 
was developed by weighting of the various clinical criteria usually used for the diagnosis 
of VAP (Table 251-7). Use of the CPIS allows the selection of low-risk patients who may 
need only short-course antibiotic therapy or no treatment at all. Moreover, studies have 
demonstrated that the absence of bacteria in gram-stained endotracheal aspirates makes 
pneumonia an unlikely cause of fever or pulmonary infiltrates. These findings, coupled 
with a heightened awareness of the alternative diagnoses possible in patients with 
suspected VAP, can prevent inappropriate treatment for this disease. Furthermore, data 
show that the absence of an MDR pathogen in tracheal aspirate cultures eliminates the 
need for MDR coverage when empirical antibiotic therapy is narrowed. Since the most 
likely explanations for the mortality benefit of bronchoscopic quantitative cultures are 
decreased antibiotic selection pressure (which reduces the risk of subsequent infection 
with MDR pathogens) and identification of alternative sources of infection, a clinical 
diagnostic approach that incorporates such principles may result in similar outcomes (1). 
Table 1-3 Clinical Pulmonary Infection Score (CPIS) 
 
 
Criterion Score 
Fever (°C)   
  38.5 but 38.9 1 
  >39 or < 36 2 
Leukocytosis   
  <4000 or >11,000/L 1 
  Bands > 50% 1 (additional) 
Oxygenation (mmHg)   
  PaO2/FIO2 <250 and no ARDS  
  
2 
Chest radiograph   
  Localized infiltrate 2 
  Patchy or diffuse infiltrate 1 
  Progression of infiltrate (no ARDS or CHF) 2 
Tracheal aspirate   
  Moderate or heavy growth 1 
  Same morphology on Gram's stain 1 (additional) 
  Maximal scorea 
  
12 
 
 
aThe progression of the infiltrate is not known and tracheal aspirate culture results are 
often unavailable at the time of the original diagnosis; thus, the maximal score is initially 
810. 
Note: ARDS, acute respiratory distress syndrome; CHF, congestive heart failure. 
 
1.1.5. Ventilator-Associated Pneumonia: Treatment: 
                                Many studies have demonstrated higher mortality rates with 
inappropriate than with appropriate empirical antibiotic therapy. The key to appropriate 
antibiotic management of VAP is an appreciation of the patterns of resistance of the most 
likely pathogens in any given patient (1). 
1.1.5.1. Resistance: 
                                 If it were not for the risk of infection with MDR pathogens, VAP 
could be treated with the same antibiotics used for severe CAP. However, antibiotic 
selection pressure leads to the frequent involvement of MDR pathogens by selecting 
either for drug-resistant isolates of common pathogens (MRSA and ESBL-positive 
Enterobacteriaceae) or for intrinsically resistant pathogens (P. aeruginosa and 
Acinetobacter spp.). Frequent use of -lactam drugs, especially cephalosporins, appears to 
be the major risk factor for infection with MRSA and ESBL-positive strains (1). 
 
